BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3912695)

  • 1. [Results of the 1st Austrian ovarian cancer study: prospective randomized comparison of a new sequential chemotherapy with 2 standard regimens in 150 stage III and IV patients].
    Sevelda P; Salzer H; Gitsch E; Karrer K
    Onkologie; 1985 Dec; 8(6):388-91. PubMed ID: 3912695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Results of the first Austrian multicenter ovarian cancer study: prospective randomized comparison of sequential chemotherapy (adriamycin/cisplatin--vincristine/cyclophosphamide--methotrexate) with 2 standard protocols (adriamycin/cyclophosphamide or adriamycin/cisplatin) in stage III and IV patients].
    Salzer H; Gitsch E; Dittrich C; Sevelda P; Karrer K; Schemper M; Stempel-Smekal G; Langer M; Wagner G; Rainer H
    Geburtshilfe Frauenheilkd; 1985 Nov; 45(11):761-8. PubMed ID: 3908214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
    Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
    J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Intermittent administration of the combination chemotherapy with cis-platin, adriamycin and cyclophosphamide (cyclic-PAC chemotherapy) for the ovarian cancers].
    Inoue M; Nakanishi K; Nakazawa A; Ogawa H; Shimizu H; Saitoh J; Tanaka Y; Ueda G; Tanizawa O
    Nihon Sanka Fujinka Gakkai Zasshi; 1990 Apr; 42(4):347-52. PubMed ID: 2358719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Results of the Hamburg ovarian blastoma study].
    Franz G; Lietz H
    Onkologie; 1985 Dec; 8(6):394-6. PubMed ID: 3937970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO III and IV) as measured by surgical end-staging (second-look surgery)--the mount sinai experience.
    Cohen CJ; Bruckner HW; Goldberg JD; Holland JF
    Clin Obstet Gynaecol; 1983 Aug; 10(2):307-24. PubMed ID: 6413114
    [No Abstract]   [Full Text] [Related]  

  • 7. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group).
    McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
    Semin Oncol; 1996 Oct; 23(5 Suppl 12):40-7. PubMed ID: 8941409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.
    Conte PF; Bruzzone M; Chiara S; Sertoli MR; Daga MG; Rubagotti A; Conio A; Ruvolo M; Rosso R; Santi L
    J Clin Oncol; 1986 Jun; 4(6):965-71. PubMed ID: 3519886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
    Wolf M; Havemann K; Holle R; Gropp C; Drings P; Hans K; Schroeder M; Heim M; Dommes M; Mende S
    J Clin Oncol; 1987 Dec; 5(12):1880-9. PubMed ID: 2824710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclophosphamide, adriamycin and cisplatin (CAP) versus cyclophosphamide, adriamycin and vincristin (CAV) in the treatment of advanced ovarian cancer: a randomized study.
    Krommer CF; Szalai JP
    Ann Oncol; 1992 Jan; 3(1):37-9. PubMed ID: 1606067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of 2 different forms of chemotherapy on remission in patients with advanced ovarian cancer].
    Krommer K; Keller G; Csaba I; Garadnay B; Göcze P
    Zentralbl Gynakol; 1990; 112(17):1105-10. PubMed ID: 2264421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chemotherapy of advanced ovarian cancer. Göttingen-Hannover studies].
    Kühnle H; Hilfrich J
    Onkologie; 1985 Dec; 8(6):374-82. PubMed ID: 3912694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effectiveness of 3-drug therapy in patients with advanced ovarian cancer].
    Kwaśniewska-Rokicińska C; Kaleta B; Kumor-Głodny T
    Ginekol Pol; 1989 Feb; 60(2):86-9. PubMed ID: 2680790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of metastatic stromal tumors of the ovary with cisplatin, doxorubicin, and cyclophosphamide.
    Gershenson DM; Copeland LJ; Kavanagh JJ; Stringer CA; Saul PB; Wharton JT
    Obstet Gynecol; 1987 Nov; 70(5):765-9. PubMed ID: 3658288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring the cytotoxic potential of a sequential polychemotherapy (adriamycin/cisplatin-vincristine/cyclophosphamide-high dose methotrexate) in patients with advanced ovarian cancer with the tumor marker CA-125.
    Sevelda P; Dittrich C; Salzer H; Pateisky N; Spona J
    Cancer Detect Prev; 1986; 9(5-6):521-8. PubMed ID: 3465442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of advanced ovarian cancer].
    de Gramont A; Krulik M; Pigne A; Brissaud P; Sirinelli A; Hubert D; Zylberait D; Debray J
    Sem Hop; 1984 Mar; 60(14):957-60. PubMed ID: 6326283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group.
    Hong WK; Nicaise C; Lawson R; Maroun JA; Comis R; Speer J; Luedke D; Hurtubise M; Lanzotti V; Goodlow J
    J Clin Oncol; 1989 Apr; 7(4):450-6. PubMed ID: 2538577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Combination chemotherapy with methotrexate, vincristine, cis-platinum, cyclophosphamide, adriamycin, and bleomycin: MVP-CAB for disseminated urological cancer].
    Fujii A; Morishita S; Nakamura I; Oka Y; Ohshima H; Nagata H; Iwamoto T; Itoh N; Nakagawa Y; Miyazaki S
    Nihon Gan Chiryo Gakkai Shi; 1990 Jan; 25(1):55-62. PubMed ID: 1691254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
    Longo DL; DeVita VT; Duffey PL; Wesley MN; Ihde DC; Hubbard SM; Gilliom M; Jaffe ES; Cossman J; Fisher RI
    J Clin Oncol; 1991 Jan; 9(1):25-38. PubMed ID: 1702144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effectiveness of cisplatin alone and in combination within the scope of primary therapy of ovarian cancer. Results of a prospective multicenter study].
    Richter P; Krafft W; Müller U; Brückmann D; Homann S; König EM; Lotze P; Morack G; Neubert S; Nöschel H
    Zentralbl Gynakol; 1990; 112(7):421-9. PubMed ID: 1695049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.